Shareholders of the largest pharmaceutical company in Nigeria, Fidson Healthcare Plc, approved a dividend of ₦1.50 per 50 kobo ordinary share, amounting to ₦3.6 billion, at the Company’s 27th Annual General Meeting held virtually on Thursday, 30 July.
The approval comes against the backdrop of a year in which the company achieved key milestones in its growth trajectory. It also coincides with the one-year anniversary of the smooth transition of leadership at both the Board and Management level — a transition shareholders acknowledged as a testament to Fidson’s strong corporate governance culture and succession planning. It also reflects shareholders’ confidence in the Company’s continued ability to deliver sustainable value despite a challenging operating environment.
The Founder and Chairman of Fidson, Fidelis Ayebae, in his address to shareholders, said 2025 marked a defining year in the history of the Company.
“We recorded revenue of ₦119.06 billion, becoming the first pharmaceutical company in Nigeria to surpass the ₦100 billion annual revenue milestone. This achievement reflects the dedication of our people, the confidence of our shareholders, and the effectiveness of our long-term growth strategy.”
